The Analyst Verdict: AbbVie In The Eyes Of 5 Experts
Portfolio Pulse from Benzinga Insights
Analysts have mixed opinions on AbbVie (NYSE:ABBV) with recent ratings showing a slight decrease in the average price target. The company's financial performance shows positive revenue growth but challenges in net margin and asset utilization.
May 17, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have mixed opinions on AbbVie with a slight decrease in the average price target. The company's financial performance shows positive revenue growth but challenges in net margin and asset utilization.
The mixed analyst ratings and slight decrease in the average price target suggest a neutral short-term impact on AbbVie's stock price. Positive revenue growth is offset by challenges in net margin and asset utilization.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100